ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,214.08
0.51%
Dow Jones
39,387.76
0.85%
US Dollar vs MXN
16.8042
0.06%
Brent Oil
84.055
0.13%
Bitcoin
62,971.98
-0.12%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Journey Medical Corporation (DERM)

  7. Journey Medical Corporation (DERM) Noticias

DERM

Journey Medical (DERM)

Journey Medical Corporation
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:DERM
FechaHoraFuenteTítuloSímboloCompañía
07/05/202407:30GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024NASDAQ:DERMJourney Medical Corporation
01/05/202415:01GlobeNewswire Inc.Journey Medical Corporation Appoints Joseph Benesch as Chief Financial OfficerNASDAQ:DERMJourney Medical Corporation
25/04/202407:30GlobeNewswire Inc.Journey Medical Corporation to Present at the Planet MicroCap Showcase: Vegas 2024NASDAQ:DERMJourney Medical Corporation
21/03/202415:01GlobeNewswire Inc.Journey Medical Corporation Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
18/03/202407:30GlobeNewswire Inc.Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of RosaceaNASDAQ:DERMJourney Medical Corporation
15/03/202407:30GlobeNewswire Inc.Journey Medical Corporation to Announce Year End 2023 Financial Results on March 21, 2024NASDAQ:DERMJourney Medical Corporation
13/03/202407:30GlobeNewswire Inc.Journey Medical Corporation to Participate in the 36th Annual ROTH ConferenceNASDAQ:DERMJourney Medical Corporation
11/03/202407:30GlobeNewswire Inc.Journey Medical Corporation Announces Presentation of Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adults at 2024 AAD Annual MeetingNASDAQ:DERMJourney Medical Corporation
23/02/202416:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DERMJourney Medical Corporation
05/01/202407:30GlobeNewswire Inc.Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
02/01/202415:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DERMJourney Medical Corporation
02/01/202415:05GlobeNewswire Inc.Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 MillionNASDAQ:DERMJourney Medical Corporation
15/12/202315:46Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DERMJourney Medical Corporation
06/12/202307:00GlobeNewswire Inc.Journey Medical Corporation Announces Successful Completion of Pre-NDA Meeting with the FDA for DFD-29 to Treat RosaceaNASDAQ:DERMJourney Medical Corporation
07/11/202315:01GlobeNewswire Inc.Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
31/10/202307:30GlobeNewswire Inc.Journey Medical Corporation to Announce Third Quarter 2023 Financial Results on November 7, 2023NASDAQ:DERMJourney Medical Corporation
20/10/202307:30GlobeNewswire Inc.Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn® (Minocycline Hydrochloride Extended-Release Tablets, 105 mg)NASDAQ:DERMJourney Medical Corporation
06/09/202307:00GlobeNewswire Inc.Journey Medical Corporation Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexza® in South Korea and Other Asian NationsNASDAQ:DERMJourney Medical Corporation
14/08/202315:01GlobeNewswire Inc.Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
10/08/202315:45Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DERMJourney Medical Corporation
08/08/202315:01GlobeNewswire Inc.Journey Medical Corporation Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
02/08/202315:01GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results on August 8, 2023NASDAQ:DERMJourney Medical Corporation
19/07/202307:30GlobeNewswire Inc.Journey Medical Corporation to Announce Second Quarter 2023 Financial Results the Week of August 7, 2023NASDAQ:DERMJourney Medical Corporation
11/07/202307:30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Results from its Two Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 for the Treatment of Papulopustular Rosacea in AdultsNASDAQ:DERMJourney Medical Corporation
03/07/202307:00GlobeNewswire Inc.Journey Medical Corporation Expects Topline Results from the Phase 3 Clinical Trials (MVOR-1 and MVOR-2) Evaluating DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the Treatment of Papulopustular Rosacea to be Announced Week of JulyNASDAQ:DERMJourney Medical Corporation
23/06/202315:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:DERMJourney Medical Corporation
13/06/202307:30GlobeNewswire Inc.Journey Medical Corporation Announces Positive Topline Data from Phase 1 Clinical Trial Assessing the Impact of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) on Microbial Flora of Healthy Adult SubjectsNASDAQ:DERMJourney Medical Corporation
22/05/202315:01GlobeNewswire Inc.Journey Medical Corporation Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
19/05/202315:01GlobeNewswire Inc.Journey Medical Corporation to Announce First Quarter 2023 Financial Results on May 22, 2023NASDAQ:DERMJourney Medical Corporation
15/05/202315:01GlobeNewswire Inc.Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:DERMJourney Medical Corporation
 Showing the most relevant articles for your search:NASDAQ:DERM

Su Consulta Reciente

USOTC
BNPQY
BNP Paribas (QX)
USOTC
RHHBY
Roche (QX)
NASDAQ
NVDA
NVIDIA
USOTC
ADDYY
Adidas (QX)
NYSE
CVX
Chevron
COIN
BTCUSD
Bitcoin
NASDAQ
TSLA
Tesla
NYSE
MRK
Merck
CCOM
SILVER
SILVER
NASDAQ
MSFT
Microsoft
NYSE
BAC
Bank of America
AMEX
XLV
Health Care Select Sector
AMEX
SPY
SPDR S&P 500
NASDAQ
QQQ
Invesco QQQ Trust Series 1
FX
USDMXN
US Dollar vs MXN
CCOM
US30
US 30
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados